William Blair downgraded Eargo from Outperform to Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/23/2021 | Outperform → Mkt Perform | William Blair | |
| 9/23/2021 | $11.00 | Overweight → Underweight | JP Morgan |
| 9/23/2021 | $10.00 | Overweight → Equal-Weight | Wells Fargo |
4 - Eargo, Inc. (0001719395) (Issuer)
4 - Eargo, Inc. (0001719395) (Issuer)
4 - Eargo, Inc. (0001719395) (Issuer)
15-12G - Eargo, Inc. (0001719395) (Filer)
S-8 POS - Eargo, Inc. (0001719395) (Filer)
S-8 POS - Eargo, Inc. (0001719395) (Filer)
William Blair downgraded Eargo from Outperform to Mkt Perform
JP Morgan downgraded Eargo from Overweight to Underweight and set a new price target of $11.00
Wells Fargo downgraded Eargo from Overweight to Equal-Weight and set a new price target of $10.00
SAN JOSE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- This quarter, Eargo, Inc. launches two new over-the-counter (OTC) hearing wellness devices, Eargo SE (launching today) and LINK by Eargo (launching in the first quarter of 2024). The new devices expand the brand's portfolio of offerings with a new earbud form factor and a completely-in-canal option focused on Eargo signature essentials. For over a decade, Eargo has set the industry standard for pairing award-winning discreet and effortless hearing devices with ongoing expert support. These newest devices address additional consumer needs around functionality, design and experience. Key highlights of each product include: Eargo SE (MSRP$1
SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo") celebrates the one-year anniversary of the creation of an over-the-counter (OTC) hearing aid category in the US. This important advancement by the US Food & Drug Administration (FDA), following a bipartisan mandate from Congress, was meant to reduce costs, increase competition, improve access, and drive innovation in the hearing aid category, resulting in more widespread adoption of hearing technology. This firmly aligns with Eargo's founding mission. The FDA has noted that the use of hearing aids has been associated with health benefits, improved social participation, and a better quality of life. Th
SAN JOSE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced an expansion of its relationship with Best Buy. Eargo devices are now on display in more than 500 Best Buy stores, marking another step in Eargo's retail journey. Approximately 250 of these Best Buy locations will carry Eargo 5–an over-the-counter, FDA-cleared and self-fitting hearing aid–allowing customers to see Eargo's virtually invisible design and purchase in store. Additionally, customers can explore Eargo's full assortment of hearing aids on BestBuy.com. Through this expansion, Eargo continues
SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t
SAN JOSE, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced the appointment of Katie Bayne to its Board of Directors, effective June 9, 2021. Ms. Bayne will serve as a member of the Nominating and Corporate Governance Committee. The appointment of Ms. Bayne fills the seat vacated by Juliet Tammenoms Bakker, following her resignation from the Board on June 9, 2021. Christian Gormsen, President and CEO, said, “We are incredibly fortunate to welcome Katie to the Eargo team. She is exceptionally qualified and brings decades of experience building one of the mos
SC 13D/A - Eargo, Inc. (0001719395) (Subject)
SC 13D/A - Eargo, Inc. (0001719395) (Subject)
SC 13G/A - Eargo, Inc. (0001719395) (Subject)
Recent Highlights: Net revenues of $8.1 million in the second quarter of 2023, up 12% year-over-yearGross systems shipped of 5,098, up 14% year-over-yearGAAP total operating loss $25.8 million in the second quarter of 2023, compared to $31.4 million in the second quarter of 2022In connection with the implementation of the announced cost reduction plan, the Company expects to extend net operating cash runway into the second half of 2024 SAN JOSE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported its financial results for the second quarter ended June 30, 2023. Will
Recent Highlights: Net revenues of $11.8 million in the first quarter of 2023, up 29% year-over-yearGross systems shipped of 8,705, up 51% year-over-yearGAAP total operating loss $22.8 million in the first quarter of 2023, compared to $30.4 million in the first quarter of 2022Commercially launched Eargo 7, a self-fitting hearing aid with the use of Sound Match via our mobile app, in February 2023Company expects modest sequential improvements to net operating cash burn in the remaining quarters of 2023 SAN JOSE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported
SAN JOSE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the first quarter 2023 after market close on May 11, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using conference ID: 2789592. The live webinar of the call may also be accessed by visiting the Events and Presentations s
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 500 points on Monday. The Dow traded up 1.67% to 32,959.68 while the NASDAQ rose 1.25% to 12,800.95. The S&P 500 also rose, gaining, 1.23% to 4,167.91. Check This Out: Top 4 Consumer Stocks That Could Blast Off This Quarter Leading and Lagging Sectors Communication services shares jumped by 2.3% on Monday. In trading on Monday, energy shares fell by 0.1%. Top Headline Western Digital Corp (NASDAQ:WDC) reported upbeat first-quarter results and announced a plan to separate its HDD and Flash businesses. Western Digital reported a first-quarter FY23 revenue decline of 26% year-on
Gainers Miromatrix Medical Inc. (NASDAQ:MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. Eargo, Inc. (NASDAQ:EAR) shares climbed 50.4% to $2.5274 after the company announced it will be taken private by Patient Square Capital. VYNE Therapeutics Inc. (NASDAQ:VYNE) gained 39.9% to $3.1399 after the company announced a private placement of $88 million and data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo. Conduit Pharmaceuticals Inc. (NASDAQ:CDT) shares gained 27.9% to $1.3042 after falling more than 12% on Friday. HeartCore Enterprises, Inc. (NASDAQ:HTCR)
Gainers Miromatrix Medical (NASDAQ:MIRO) shares increased by 217.2% to $3.3 during Monday's regular session. The current volume of 2.9 million shares is 15262.3% of Miromatrix Medical's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $90.0 million. Eargo (NASDAQ:EAR) stock moved upwards by 52.38% to $2.56. Trading volume for Eargo's stock is 3.0 million as of 13:30 EST. This is 8069.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $53.1 million. Reviva Pharmaceuticals (NASDAQ:RVPH) stock increased by 43.25% to $5.37. Trading volume for this security as